Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-11-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于股东部分股份解除冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the unfreezing of a portion of shares held by a shareholder (Chen Guoxing) in Shanghai Medicilon Inc. It details the number of shares unfrozen, the percentage of total shares, and the impact on company control. There is no financial data, no report attached or referenced as being published, and no mention of management changes or legal proceedings beyond the share freeze status. This fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about shareholder share status that does not fit other specific categories.
2025-11-12 Chinese
美迪西：股东减持计划时间届满暨减持结果公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Shanghai Medicilon Inc. regarding the completion of a shareholder's stock reduction plan. It details the shareholder's holdings before and after the reduction, the number of shares reduced, the time period of the reduction, and confirms that the reduction plan period has ended. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about a shareholder's transaction in their own shares, specifically a reduction in holdings. This fits the category of 'Transaction in Own Shares' (POS). The document length is short (1753 characters), and it is not an announcement of a report publication but a substantive disclosure of share transactions by a shareholder.
2025-11-11 Chinese
美迪西：2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of Shanghai Medicilon Biopharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, and cash flow statements for the first nine months of 2025. The report explicitly states it is a quarterly report and includes unaudited financial statements. The presence of comprehensive financial data for a period shorter than a full fiscal year (the third quarter) confirms it is an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification document, so it is not an RPA or RNS. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2025
2025-10-30 Chinese
美迪西：关于参加2025年上海辖区上市公司三季报集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in a collective performance explanation meeting for the 2025 third quarter report. It provides details about the meeting time, location, participants, and how investors can join and ask questions. The document does not contain actual financial statements or detailed financial analysis but rather informs about the upcoming investor presentation event related to the quarterly report. The document length is short (1569 characters) and serves as a notice for the event rather than the report itself. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the full Interim/Quarterly Report (IR).
2025-10-30 Chinese
美迪西：2025年员工持股计划完成股票非交易过户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a non-trading stock transfer related to the company's 2025 employee stock ownership plan. It details the number of shares transferred, the price, the participants, and the lock-up period. The document is relatively short (1223 characters) and focuses on the progress and implementation of an employee stock plan, not a full financial report or detailed financial data. It is an update on capital structure related to employee stock ownership, specifically a stock transfer announcement. This fits best under the category of Capital/Financing Update (CAP), as it relates to financing activities and capital structure changes involving employee stock plans.
2025-10-28 Chinese
美迪西：关于股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the partial release of pledged shares by a shareholder named Lin Changqing. It details the number of shares released from pledge, the remaining pledged shares, and their proportions relative to the shareholder's total holdings and the company's total share capital. The document is short (817 characters) and focuses solely on share pledge status changes, without any financial statements, management discussion, or regulatory certifications. This fits the category of a Transaction in Own Shares (POS), which covers company share buybacks, sales, or changes in pledged shares by shareholders or insiders. It is not an annual report, earnings release, or regulatory filing. Therefore, the correct classification is POS with high confidence.
2025-10-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.